Blood Gas Analyzers Patents: Leaders, Trends & White Space 2026
Blood Gas Analyzer Patents: Who Holds the Claims and Where the Gaps Sit
Filings have cooled from their peak. 2021 was the high point at 124 filings; by 2024, the last complete year, that had fallen to 49, a 60% drop across the span. Filings rose from 63 in 2017 to a peak of 124 in 2021, then fell to 49 by 2024 — a 60% drop over that three-year span. 2025 and 2026 figures are not yet comparable, since publication typically lags filing by roughly 18 months.
- 1CORTHERA INC5.9%
- 2HEMANEXT INC5.3%
- 3VANDERBILT UNIV4.7%
- 4ALEXION PHARMACEUTICALS INC2.7%
- 5HOSPIRA INC2.6%
See the full blood gas analyzers analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who holds the most patents on blood gas analyzers?
The dataset’s leading assignee holds 86 patent families out of 1,466 in scope, which is a meaningful lead over fifth place at 38 families. Even so, the top five assignees combined account for only 21.1% of all records, and the top ten reach 32.0%. That means no company controls the field outright; ownership is concentrated at the very top but thins out quickly after that.
Is the blood gas analyzer patent field growing or shrinking?
Filing activity rose from 63 in 2017 to a peak of 124 in 2021, then fell to 49 by 2024, a 60% decline over that three-year span. 2024 is the most recent year with complete data; figures for 2025 and 2026 are still filling in because publication typically lags filing by about 18 months, so it is too early to call the current trajectory. Based on complete years, the field has contracted from its 2021 high.
What technology areas do blood gas analyzer patents cover most?
By IPC subclass, medicinal preparations (A61K) and therapeutic activity (A61P) account for the largest shares of the 1,466 records, at 57.0% and 32.7% respectively. Material analysis and testing (G01N) and diagnosis and surgery (A61B) — the classes closest to sensor and device engineering — cover 19.2% and 15.1%. This split reflects a dataset weighted toward chemistry and therapeutic framing rather than pure hardware claims.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Blood Gas Analyzers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.